Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer. Artigo Académico uri icon

autores

  • Santos FA
  • RUI MANUEL VIEIRA REIS
  • Barroti LC
  • Pereira AAL
  • Matsushita MM
  • de Carvalho AC
  • Datorre JG
  • Berardinelli GN
  • Araujo RLC

data de publicação

  • agosto 1, 2023